<DOC>
	<DOCNO>NCT02070484</DOCNO>
	<brief_summary>The purpose study compare effect safety NuCel DBX patient undergo posteriolateral lumbar spinal fusion degenerative disc disease .</brief_summary>
	<brief_title>Efficacy Human Amniotic Tissue-derived Allograft , NuCel , Patients Undergoing Posteriolateral Lumbar Fusions Degenerative Disc Disease</brief_title>
	<detailed_description />
	<mesh_term>Spinal Diseases</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Spondylolisthesis</mesh_term>
	<mesh_term>Spinal Stenosis</mesh_term>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<mesh_term>Musculoskeletal Diseases</mesh_term>
	<mesh_term>Intervertebral Disc Displacement</mesh_term>
	<mesh_term>Spondylosis</mesh_term>
	<mesh_term>Spondylolysis</mesh_term>
	<criteria>Between age 18 75 year Symptomatic , singlelevel degenerative lumbar disc disease , spondylosis spondylolisthesis Failed conservative treatment Low risk nonunion Must candidate singlelevel , posteriolateral lumbar spine fusion Must able willing give Informed Consent Englishspeaking Smoker ( smoke â‰¤3 month prior consent ) ; ( Patel et al . 2013 ) Patients poorly control diabetes mellitus ( HgbA1c &gt; 7 % ) Documented osteoporosis Prior lumbar spinal surgery spinal level , immediately adjacent spine level , level operate Back pain due infection , tumour , metabolic bone disease Terminal disease , HIV infection , neoplasm Autoimmune disease , rheumatoid arthritis Morbid obesity ( body mass index ( BMI ) 35 kg/m2 ) Major psychiatric illness last year History alcohol drug abuse last year Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>NuCel</keyword>
	<keyword>Lumbar Spine</keyword>
	<keyword>Degenerative Disease</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Fusion</keyword>
</DOC>